What McKesson Ventures' Finding That AI Makes Enterprise Sales Easier Means — August 25, 2026
· CompaniesAutomation
Flash edition of the Radar: McKesson Ventures publishes a survey of 103 investors and founders where AI appears as the primary driver for enterprise purchasing. 63% of investors have more interest, 47% of founders find selling easier, and per-user pricing drops to 16%. What it means for your company.
Flash Edition. McKesson Ventures, the investment arm of one of the world's largest healthcare distributors, today published a survey of 103 investors and founders that answers a question reaching far beyond pharma: does AI truly open the enterprise buying door, or just the pilot door? A complement to this morning's Radar: where that looked at supply; this measures demand.
What Happened
The report, Pharma tech innovation: Voices from the builders and their backers, collects responses from May 2026 from 54 investors and 49 entrepreneurs selling technology to pharmaceutical companies (Source). 63% of investors say their interest in the sector has risen in three years compared to other healthcare areas, and the most cited reason is increased buyer interest in adopting AI (60%), ahead of larger budgets (54%) and the opportunity to replace legacy systems (51%). On the selling side, nearly double the founders (47%) say selling has become easier compared to 24% who find it harder; the drivers are executive committee sponsorship (65%) and that same appetite for AI (61%) (Source).
Why It Matters
Two signals apply to any sector. First: per-user pricing has become the minority. 29% charge by usage, 24% use a hybrid model, 18% by outcome, and only 16% per seat, and more than three-quarters have changed their model since launching. It is the logical consequence of software moving from assisting a person to doing the work: if there isn't one person per license, charging per license stops making sense. Second: the gap between narrative and cash. 63% of investors report more interest, but only 43% of founders perceive it; investors cite rising budgets (54%) much more than founders (22%), and shorter sales cycles (23% vs. 13%). Those putting the money in see more movement than those billing it. The report closes with the order of magnitude: AI investment in pharma is expected to grow from around $4 billion to $25 billion by 2030 (Source).
For Your Company
Three moves. One, if you sell AI services or software: review your pricing today, because the fastest-adopting market no longer buys seats—it buys usage or outcomes. Two, if you buy: 65% say what unclogs adoption isn't the vendor, it's sponsorship from the top—appoint a committee sponsor with their own budget before choosing a tool, or the pilot will die at the demo stage no matter how good it is. And three, the uncomfortable stat: only 39% mention moving from pilot to production with agility. The bottleneck remains integration, data, and governance: budget for production deployment from day one.
Frequently Asked Questions
What does the August 25, 2026, McKesson Ventures report say?
That AI is the main driver of the sector according to both sides of the market: 63% of the 54 surveyed investors have more interest than three years ago, and 47% of the 49 founders sell with more ease. The fieldwork was conducted in May 2026.
Does this only apply to the pharmaceutical sector?
The field of study is pharma, but the patterns are transversal: executive sponsorship as a buying unlocker, the migration from per-user pricing to usage or outcome pricing, and the leap from pilot to production as the bottleneck.
Why don't investors and founders see the same thing?
Because they measure different things: the investor looks at the aggregate market signal and the founder at their pipeline. If 54% of investors see budgets rising and only 22% of founders notice it, the money exists but is not yet allocated to executable line items.